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State M a n d a t e d Prenatal H u m a n Immunodeficiency
Screening at a Large C o m m u n i t y

Virus

Hospital

W I L L I A M C U S I C K , M . D . , J U L I E S T E W A R T , F.N.P., M I C H A E L P A R R Y , M . D . ,
GAVIN McLEOD, M.D., GERALD RAKOS, M.D., CHRIS SULLIVAN, M.D.,
AND JOHN RODIS, M.D.
ABSTRACT— Purpose: To describe the initial experience of state mandated prenatal HIV screening
at a large community hospital. Methods: HIV
screening was provided to all pregnant women as of
October 1,1999. All HIV-positive women identified
received aggressive ahtiretroviral therapy to reduce
the likelihood for vertical transmission. Neonates
were screened for HIV at zero, six, and 12 months of
age. Results: Seven pregnant women (0.3%) and
two additional family members tested positive for
HIV. All seven infants born to the identified HIVpositive women have tested negative for infection.
We estimated that six of nine cases of HIV infection
identified would have been missed under a policy of
voluntary HIV screening. Conclusions: Universal
screening for HIV in pregnancy is achievable and
desirable and provides the best opportunity to minimize the number of new neonatal HIV infections.
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Introduction

I

NFECTION with the Human Immunodeficiency Virus
(HIV), the virus responsible for Acquired Immunodeficiency Syndrome (AIDS) remains a significant public
health concern. Although available drug therapies have
greatly improved the quality of life and survival times for
HIV-infected individuals, death from complications of
the infection eventually occurs. Without a cure, preventing the spread of HIV infection is central in controlling the
disease. To this end, avoidance of activities associated
with HIV transmission is essential.

Pregnant mothers infected with HIV can transmit the
virus to their infant during the course of pregnancy and
delivery. Vertical transmission of the virus from the HIVinfected gravida to the neonate accounts for the majority
of new pediatric HIV infections. This vertical transmission rate can be substantially reduced with aggressive
antiretroviral treatment of the HIV-infected mother during the antepartum and intrapartum period combined with
neonatal treatment of exposed infants.1,2:3 To achieve this
benefit, however, one must first identify all infected mothers. Voluntary prenatal screening for HIV infection has
improved the rate of antepartum HIV testing in the mother,
but still many women go untested.4,5 In response to this
deficiency of voluntary screening, the State of Connecticut, in October 1999, implemented legislation advising
health-care providers to inform patients that HIV screening was part of routine obstetrical care (State of Connecticut, House Bill No. 7501; June 1999 Special Session,
Public Act No. 99-2). The purpose of this study is to report on the impact of mandatory prenatal HIV screening
at a large community hospital during the initial 10 months
following enactment of the legislation.

Materials and Methods
In October 1999, statewide implementation of Connecticut House Bill # 7501 required health-care providers to inform their pregnant patients that HIV testing is
part of routine obstetrical care. Pregnant women would
be provided with pre- and post-test counseling and informed of the confidentiality of the test result. The principle features of this legislation regarding antenatal HIV
screening were:
1. Health-care providers giving prenatal care to pregnant
women in this state shall inform her, or ascertain from
the women's medical record that such information has
already been provided to her, that HIV testing is part of
routine prenatal care and shall inform her of the health
benefits to herself and newborn of being tested for HIV
infection;
2. HIV testing shall be performed within 30 days of the
first examination and again between 26-28 weeks gestation or shortly thereafter;
3. If such testing is not documented in the medical record
at time of admission for delivery, HIV testing of the
pregnant women will be performed in the absence of
written objection; and
4. Newborn HIV screening will be performed unless
maternal HIV status is documented.
A team comprised of counselors, a family nurse practitioner, infectious disease, and maternal-fetal medicine specialists coordinated the prenatal HIV-screening program
and supervised the treatment of alL pregnant HIV-positive women identified. Pregnant women were aggressively
managed with highly active antiretroviral treatment.
Zidovudine (AZT) was always a component of the antepartum regimen. Change in medical management was
based on response to therapy as determined by HIV viral
load and maternal CD4 levels. In addition, AZT was administered intrapartum and postnatally to the infant as per
the Pediatric AIDS Clinical Trial Group 076 Study prophylaxis regimen.1 Standard intrapartum practices to
lessen the risks of vertical transmission were practiced,
e.g. the avoidance of fetal scalp electrodes. Cesarean section was not routinely performed; however, patients were
counseled regarding the potential for reduced neonatal
transmission with elective cesarean section. Neonatal HIV
testing was performed at zero, six, and 12 months of life.
The period of study is October 1999 through July 2000.
Results
A total of 2,352 infants were born to 2,239 mothers at
our community-based, university affiliated teaching hospital during the study period. The racial profile at our in-

stitution is as follows: white: 62%,hispanic: 17%, black:
14%, other: 7%. The majority of our patients are insured
(78%); 22% are uninsured or covered by medicaid. All
women delivered during the study period were screened
for HIV. Seven pregnant women (0.3%) tested positive
for HIV infection. Six of seven women were identified
prior to their admission for labor. The seventh patient,
having refused voluntary HIV screening earlier in the pregnancy, tested positive for HIV on admission for labor. On
follow-up testing, two additional family members of HIVinfected women also tested positive: the 18-month old
child of one patient and the spouse of another. Of the nine
individuals detected, 8/9 had no prior knowledge of their
HIV status. A single patient did not disclose her known
HIV-positive status at her initial prenatal visit but acknowledged her positive status after her initial HIV prenatal
screen returned positive.
The six HIV-positive pregnant patients detected
antenatally agreed to treatment during pregnancy with
highly active antiretroviral therapy (HAART) in addition
to intrapartum, postnatal AZT treatment. Four of six patients received zidovidine/lamivudine (Combivir) and
nevirapine (Viramune) antenatally. The HIV viral load was
undetectable at term in three of these women and was
reduced to 477 copies in the fourth. Three out of four of
these women were delivered vaginally at term; the fourth
(undetectable viral load) was delivered at term by repeat
cesarean section. A fifth woman received antenatal treatment with zidovidine/lamivudine (Combivir) and abacavir
(Ziagen). Her HIV viral load was reduced to undetectable levels by term and she was delivered vaginally. A
sixth patient initially treated with zidovidine/lamivudine
(Combivir) and nevirapine (Viramune) showed persistent
HIV viral load elevations and required the addition of
nelfinavir (Viracept). Her HIV viral load was reduced to
420 copies by term when she was delivered vaginally.
The patient who tested positive for HIV on admission to
labor received no antenatal or intrapartum treatment; however, her infant received neonatal AZT therapy once maternal HIV infection was documented. Her HIV viral load
at time of diagnosis was 137,000 copies. All seven infants have tested negative for HIV infection.
Discussion
Early in the history of HIV infection prior to proven
drug therapies, anonymous neonatal screening was performed primarily to establish the seroprevalence of HIV
infection in pregnancy.6,7 Subsequently, with the advent
of effective antiretroviral treatments that improved survival, attention was focused on the early identification of
infected individuals. In pregnancy, voluntary HIV screening was advocated in an effort to identify HIV-infected
women.8 With time it became clear that HIV-infected
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gravidas could transmit the infection to their infants. Vertical transmission was found to occur in up to 25% of
neonates born to untreated HIV-infected mothers.9 In 1994,
zidovidine therapy administered in the antenatal, intrapartum, and neonatal period could reduce the rate of maternal-infant HIV transmission by two-thirds.1 Further
additions to the HIV treatment armamentarium allowed
for greater control of maternal HIV infection and led to
further reductions in the vertical transmission rate. With
multidrug therapy, maternal-infant transmission rates have
been reduced to 1% to 2%.23 This remarkable success in
preventing new cases of neonatal HIV infection can be
realized only if the infected gravida is identified and
treated. The nature of HIV infection and its public health
implications demands a coordinated approach to limit the
spread of the infection wherever possible.
In the United States today, mandatory HIV counseling
with voluntary screening of pregnant women is the most
common form of antenatal screening performed. This
screening approach followed the 1995 recommendation
of the United States Public Health Service.8 Although this
antenatal HIV screening policy has succeeded in identifying many infected women, only 58% to 81 % of women
consent to voluntary screening.4 The reasons for refusal
of voluntary antenatal HIV screening are many but include both patient and physician factors. Some patients
may decline voluntary screening based on a perception
of no risk for HIV infection. Other patients, with a history of drug use and/or prior sex partners, may not acknowledge such history and refuse voluntary screening
out of fear of arousing suspicion in their current partner.
Still other patients at high risk for HIV infection may decline voluntary screening out of fear of testing positive
for the infection. The counseling style of the individual
physician may have a significant influence on the rate of
acceptance of voluntary screening. Physicians who perceive their patients to be without risk for HIV infection
or those who fail to recognize the importance of antenatal

Table 1. —Prenatal HIV cases at The Stamford Hospital,
1992-2000
Year

Prenatal
Case

HIV
HIV
Positive Infant Negative Infant

1992

3

3

0

1993

2

0

2

J 994

1

0

1

1995

2

1

1

1996

3

1

2

1997

3

0

1*

1998

4

0

3

1999

9

1

8

6
0
*status unknown in two infants

6

2000

HIV screening may rj,ave low rates of patient acceptance
for voluntary HIV screening. Conversely, physicians more
familiar with the inadequacies of screening based on risk
factors alone may be more committed to antenatal HIV
screening and thus have a higher percentage of patients
accepting testing.10
The importance of identifying HIV-infected pregnant
women and reducing neonatal HIV infection combined
with the deficiencies of voluntary prenatal HIV screening led to a change in prenatal HIV screening in the state
of Connecticut. A policy of universal prenatal HIV screening was readily integrated by the local health-care providers and universally accepted by patients in our institution. When fully implemented, this revised state policy
of mandated prenatal screening would achieve the objective of universal prenatal screening and would afford the

Table 2. —Children born to mothers with HIV, State of Connecticut 1995-2000
Year

Total
n

HIV Positive
n (%')

HIV Negative
n

HIV Pending
n

HIV Unknown
n

1995

76

8 (11.9%)

59

0

9

1996

64

4 (6.9%)

54

1

5

1997

68

2 (3.2%)

60

5

1

1998

63

1 (1.9%)

52

9

1

1999

69

4 (6.0%)

63

2

0

2000

74

0 (0 %)

60

13

1
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best opportunity of preventing vertically acquired neonatal HIV infection. Prior to state mandated prenatal HIV
screening, many patients attending the hospital based
obstetrics clinic underwent voluntary screening. We assumed that the three patients identified in this hospitalbased clinic would have been detected under a policy of
voluntary prenatal HIV screening. We estimated the remaining six cases (66.7%) would have gone undetected
under the prior policy of voluntary prenatal HIV screening. In the first 10 months of mandated prenatal HIV
screening, seven pregnant women were screen positive
for HIV. Assuming a 25% vertical transmission rate without therapy, we estimated that two case of neonatal HIV
infection were prevented with a policy of mandatory prenatal HIV screening; we estimate that one of these cases
would have been missed under a policy of voluntary
screening. The prevention of a single case of a lethal disease makes a strong argument for universal HIV screening in pregnancy.
The impact of a policy of universal prenatal HIV screening combined with aggressive antepartum, intrapartum,
and neonatal HIV therapy is reflected in our institutional
numbers over the past 10 years (Table 1). Under a policy
of voluntary screening (1992-1998), one to three cases
of HIV in pregnancy were documented. With institution
of universal screening, 15 cases were identified between
1999-2000. Prior to AZT monotherapy for prevention of
vertical transmission of HIV the vertical transmission rate
at our hospital was 40% (2/5). With AZT monotherapy,
the vertical transmission rate in infants with known follow up was 29% (2/7). Since the utilization of HAART in
pregnancy in 1997, only a single case tl/19,5.5%)of HIV
infection has been documented in exposed neonates. The
reduction in neonatal HIV infection documented at our
institution has mirrored the success experienced statewide.
In the years 1995-2000, the reported number of prenatal
HIV cases has remained relatively constant (Table 2). A
slight increase in the number of prenatal HIV infection
was recorded in the first two years (1999,2000) of mandated prenatal HIV screening. In contrast, the rate of neonatal HIV infection has declined from 11.9% in 1995 to
,1.9% after mandated HIV screening. In 2000, the first,
full year of mandated prenatal HIV screening, all sixty
neonates with known follow-up born to HIV-positive
mothers have tested negative for the infection (Connecticut Department of Public Health, Connecticut HIV/AIDS
Statistics Through December 31, 2001, www.dph.state.
ct.us/BCH/infectiousdise/aids_case_data.htm).
Despite a marked reduction in the number of perinatally
acquired HIV infants from a peak of 1,000-2,000 during
the early 1990s, an estimated 300-400 babies continue to
be born with-HIV yearly in the United States. Many of
these infants are born to women who were not tested for

10

HIV before delivery (CDC data, 2001). The initiative towards universal prenatal HIV screening was outlined in
the United States Public Health Service revised statement
regarding HIV screening of pregnant women issued in
2000." In our experience, universal screening for HIV in
pregnancy was readily accepted by the informed patients
and proved highly effective. As illustrated by the institutional and statewide data presented, universal screening
for HIV infection in pregnancy affords the best opportunity to prevent many cases of neonatal HIV infection that
continue to occur with voluntary prenatal HIV screening.
Prevention of HIV is less costly than treatment. It is likely
that a policy of universal screening for HIV in pregnancy
may prove cost effective.12,13 The tremendous individual
and societal burden of HIV infection warrants an aggressive health-care policy to reduce the spread of the infection. The time for voluntary screening for HIV infection
in pregnancy has passed. With the advent of effective
antenatal and neonatal therapies to prevent new cases of
neonatal HIV infection, the time for universal prenatal
HIV screening has arrived.
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